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OBJECTIVES: The aims of this study were (1) to determine the change in patients’ 
knowledge about their disease and treatment; (2) to assess the percent change in 
values of glycated hemoglobin (HbA1c) and change in blood pressure in mmHg; 
and (3) to evaluate adherence status, measured through pill counts. METHODS: A 
prospective study was conducted using patients with a diagnosis of both T2DM and 
hypertension at Arauco hospital in Arauco, Chile. Each patient participated in three 
interviews over a period of six months. The study incorporated a tailored pharmaco-
therapeutic intervention plan that included written and oral information regarding 
pathologies and pharmacological treatment. To determine treatment adherence, a 
pill count method was performed during each interview. Change in patient adher-
ence and knowledge of the diseases and treatments was assessed using the Fisher 
exact test. The difference in HbA1c and blood pressure between the initial and final 
sessions was evaluated using Student’s t-test. Analyses were performed using SPSS 
version 17. RESULTS: A total of 50 patients were selected, of whom 33 (66%) were 
female. At the beginning of the program, 30% of patients were found to be adherent. 
At the end of the study, this number had increased to 46% (p-value: 0.099). 10% of 
patients had full knowledge of their disease at baseline. At the end of the study, this 
number had increased to 66% (p-value < 0.001). After the completion of the inter-
views, significant decreases were observed for HbA1c (p-value < 0.001), and systolic 
blood pressure (p-value < 0.001). Stratified by sex, stronger and more significant 
decreases were observed for females in terms of both HbA1c (0.63%, p-value= 0.003) 
and systolic blood pressure (17 mmHg, p-value < 0.001). CONCLUSIONS: A pharma-
cotherapeutic optimization plan based on improved patient adherence and knowl-
edge and implemented for patients with chronic conditions, such as T2DM and 
hypertension, has had a positive impact on therapeutic outcomes.
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OBJECTIVES: The aim of the study is to develop and validate a decision aids (DA) fro 
Arabic depressed patients. METHODS: A six-page DA booklet published by Agency 
for Health Care Research and Quality (AHRQ) was adapted and translated to Arabic 
using Brisling’s back translation model. The work of Al-Muhtaseb was followed to 
produce a natural Arabic text. Validation was carried out by 24 experts (Physicians, 
Pharmacists, Academic staff and depressed Patients).International Patient Decision 
Aid Standards (IPDAS) Criteria Checklist was used to examine the DA structure 
and content. RESULTS: Experts strongly agree that the DA will increase patient’s 
recognition, knowledge and understanding of their condition and options, based 
on (IPDAS). 83% of experts report that DA provide information about options in 
sufficient detail for decision making, 68% present probabilities of outcomes is an 
unbiased and understandable way, 85% clarifying and expressing patients values 
and 87% for structure guidance in deliberation and communication with a total of 
81% for the whole content criteria. Secondly, the development process has 63% posi-
tive feedback. Particularly, 83% agreed that the information are present in balanced 
manner, 65% for having a systematic development process, 71% for using a scientific 
evidence data , 69% for using plain language but less than half of the experts agreed 
with the disclosing conflicts of interest. Finally, the sum of expected effectiveness 
criteria got a very high percentage (93%). In addition, experts provided constructive 
feedback with some modification regarding the language and general layout of the 
DA. CONCLUSIONS: Up to our knowledge we developed and validated the first 
Arabic DA based on IPDAS criteria for depressed patients. Future research needed 
to assess the effectiveness of this DA on depressed patient involvement in SDM.
PHS79
imPact of StructureD Patient eDucation on quality of life of SoutH 
inDian DiabeticS
Talla V.1, Yellu N.R.2, Pippalla S.R.3, Rao V.1, Pattnaik S.1, Subudhi S.4, Budike R.1,  
Pandalaneni A.3
1Talla Padmavathi College of Pharmacy, Warangal, India, Warangal, India, 2University College 
Of Pharmaceutical Sciences, Kakatiya University, Warangal, India, 3Talla Padmavathi College Of 
Pharmacy, Warangal, India, 4Talla Padmavathi Pharmacy College, Warangal, Warangal, India
OBJECTIVES: The normal life of patients is seriously affected by Diabetes Mellitus 
(DM). According to Diabetes Atlas it is estimated that 61.3 million people live with 
diabetes in India (2011 estimates) and77.2 million pre-diabetics. The objective of this 
study was to evaluate the impact of clinical pharmacist intervention by counselling 
on medication adherence and quality of life of diabetic patients. METHODS: The 
study sample was extracted from a reputed diabetic clinic of Warangal, India over 
a period of six months. About 175 patients diagnosed with diabetes were recruited 
and were randomized into test (n= 85) and control (n= 90). Health Related Quality 
of Life of patients was assessed using 19 domain Audit of Diabetes Dependent 
Quality of Life (ADDQoL) questionnaires and medication adherence was assessed 
using Brief Medication Questionnaire (BMQ). BMQ and ADDQoL questionnaires 
were administered at baseline and subsequent four follow-ups each of one month 
duration. Test group patients administered with structured patient education by 
using various counselling aids on monthly basis and controlled group patients 
were deprived of the same. The data was subjected to relevant statistics. RESULTS: 
The study reveals that there is a highest impact of patient education on working 
life, physical activity, financial condition and their freedom to eat and drink fol-
lowed by other quality of life domains in diabetic patients. The mean fasting blood 
sugar and post prandial blood sugar values of each phase were correlated and was 
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OBJECTIVES: To compare the medication adherence and persistence of existing 
users of chronic medications enrolled in a pharmacy chain’s appointment-based 
medication synchronization (ABMS) program, with patients who are not enrolled in 
the program for the duration of one year. METHODS: A retrospective cohort study 
compared patients receiving ABMS with matched controls receiving usual standard 
care. ABMS consisted of an appointment to synchronize the patient’s medications to 
be dispensed on a single appointment day every month, a call to the patient prior to 
the appointment day to address any prescription changes and to remind the patient, 
and a patient visit to the pharmacy to pick up the medication. Outcomes meas-
ured were 1-year adherence rates using proportion of days covered (PDC) and 1-year 
non-persistence rates. Data for this study came from prescription claims records of 
patients taking one of six chronic medication classes during the period of December 
1, 2011 to February 28, 2014. ABMS patients were matched with controls on prior 
adherence behavior, medication class, age, gender, and geographic region. RESULTS: 
Mean PDC scores ranged from 0.73 to 0.91 for ABMS patients, and from 0.57 to 0.71 for 
controls depending on the medication class. The percentage of adherent individuals 
(i.e., PDC≥ 0.8) was 55% to 84% for ABMS participants and 37% to 62% for controls. Odds 
of adherence was 2.3 to 3.6 times greater with ABMS. Controls became non-persistent 
(61% to 74%) more often than ABMS patients (33% to 44%) with hazard ratios of non-
persistence being 0.39 to 0.67 for individuals in the program. Compared to controls, 
study patients had a 33% to 61% lower likelihood of non-persistence, depending on 
the drug class. CONCLUSIONS: ABMS program in a community pharmacy setting was 
associated with significant improvements in adherence and persistence for patients 
who were existing users of chronic medications for at least six months.
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OBJECTIVES: To examine the difference in the adherence of patients with metabolic 
syndrome receiving a hybrid model of care compared to other community phar-
macy models. METHODS: Prospective, randomized-control trial design conducted 
through an integrated delivery network in Northwest Ohio. Patients required to 
have Paramount health insurance, type 2 diabetes, hypertension, hyperlipidemia, 
prescribed at least five oral medications, and prescribed an oral medication for each 
disease state. Patients randomly assigned to one of four groups. The first group 
received standard pill bottles. The second group received adherence packaging and 
refill synchronization. The third group received pill bottles and medication therapy 
management (MTM) using an appointment-based model. The fourth group received 
the hybrid model, including adherence packaging, refill synchronization, and MTM 
using the appointment-based model. Adherence was measured using patient-
reported pill count. RESULTS: The sample (n= 26) was predominantly female, aver-
age age 61 years. Types of insurance included Medicaid(7.14%), Medicare(28.57%), 
and commercial insurance(64.29%). Adherence ranged from 29% to 100% among all 
participants. Interim, three-month results showed that the greatest improvement in 
medication adherence over time was seen in the hybrid model group, from 23.6% to 
81.6%. CONCLUSIONS: These preliminary results show that the hybrid model group 
has the potential to positively impact medication adherence. This is an ongoing 
study. Further results are needed to fully analyze the benefit of the hybrid pharmacy 
practice model of care.
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OBJECTIVES: Adherence to antiretroviral therapy (ART) is a main concern in the 
control of HIV and is associated with treatment success or failure. The aim of this 
study was to determine adherence to ART using three methods and to identify fac-
tors related with non-adherence. METHODS: The study included 225 HIV patients 
under treatment at Regional Hospital in Concepción, Chile. Adherence was meas-
ured through two indirect methods: (1) the simplified medication adherence ques-
tionnaire (SMAQ), a survey including four questions with dichotomous answers, one 
question with a categorical answer, and one question with an open answer; and (2) 
a pharmacy dispensation register (PDR), which measures adherence through a ratio 
defined as number of days for which the supply of medication dispensed was pre-
scribed divided by days between prescription fills; and through one direct method: 
(3) measuring viral load and CD4+ cell count. These methods were compared and a 
global weighted adherence measure was calculated for the 47 patients that received 
all three evaluations. RESULTS: According to the SMAQ, 51% of patients were adher-
ent; while 43% were adherent according to PDR, and 50% were adherent according 
to the direct method. Weighted adherence was 21%. Main causes of non-adherence 
were: delay in medication refill (43%); lack of information regarding ART (43%); 
forgetting doses (36%); and adverse reaction (35%). Patients were more adherent to 
treatment with the combination of two nucleoside reverse transcriptase inhibitors 
and one non-nucleoside reverse transcriptase inhibitor (33%) than with the same 
combination plus protease inhibitor (12%). CONCLUSIONS: Adherence to HIV treat-
ment was below the Chilean average. Because the global weighted average was 
significantly less than the individual adherence percentages, each method alone 
is not sufficient to obtain a reliable determination of adherence. An evaluation of 
the impact of non-adherence behavior on the Chilean national HIV program is 
recommended.
